Decintas 50 Injection

Composition Decitabine (50mg)
Rx Prescription Required
Pack vial of 1 Injection
Storage Store below 30°C
Chemical Class Azacitidine Derivative
Action Class Antimetabolites
Habbit Forming No
Manufacturer Intas Pharmaceuticals Ltd
Manufacturer address Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad – 380009. Gujarat. India.

Decintas 50 Injection is also used with certain other medicines as part of combination chemotherapy. It is given as an injection into the vein under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

The most common side effects of this medicine include nausea, vomiting, diarrhea, headache, fever and lung infection. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.

Before taking it, tell your doctor if have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. Use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Myelodysplastic syndrome
Blood cancer

Your doctor or nurse will give you this medicine. Kindly do not self administer.

Decintas 50 Injection interferes with the growth of DNA and RNA of the cancer cells by substituting their building blocks. It prevents the cancer cells from growing and multiplying.

Information not available at the moment. Please check back later.

Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine.

Inform your doctor immediately if you notice any signs of infection such as fever, sore throat, rash or severe diarrhea.

Q. Is Decintas 50 Injection a vesicant?

Decintas 50 Injection is not a vesicant and is not known to cause severe local tissue damage upon extravasation (leaking of injected Decintas 50 Injection into the surrounding tissues from the site of administration) when injected.

Q. How effective is Decintas 50 Injection?

The effectiveness of Decintas 50 Injection depends upon several factors including the patient’s clinical condition, number of treatment cycles etc. and may vary depending upon the individual response.

Q. Does Decintas 50 Injection cause hair loss?

Yes. Hair loss (alopecia) is among the known side effects of Decintas 50 Injection.

Q. How is Decintas 50 Injection administered?

Decintas 50 Injection comes as a powder to be to be added to fluid and injected slowly over 3 hours into a vein (slow i.v infusion) by a doctor who is experienced in giving chemotherapy medications for cancer in a hospital or a clinic.

In Myelodysplastic syndrome

Decintas 50 Injection is used to treat myelodysplastic syndrome, a group of conditions in which the bone marrow produces blood cells that are abnormal in structure and function, and does not produce enough healthy blood cells. Decintas 50 Injection kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

In Blood cancer

Blood cancer, also called leukemia, is a cancer of the blood-forming tissues, that decreases the body’s ability to fight infection. Decintas 50 Injection kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective medicine but you should discuss the side effects and benefits of this medicine with your doctor. Let your doctor know if any of the side effects bothers you.show moreshow less

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Pneumonia

Diarrhea

Low blood platelets

Anemia (low number of red blood cells)

Nosebleeds

Decreased white blood cell count (neutrophils)

Lung infection

Fever

Headache

Vomiting

Nausea

Alcohol:CONSULT YOUR DOCTOR

It is not known whether it is safe to consume alcohol with Decintas 50 Injection. Please consult your doctor.

Pregnancy:CONSULT YOUR DOCTOR

Decintas 50 Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

Breast feeding:UNSAFE

Decintas 50 Injection is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.

Driving:UNSAFE

Decintas 50 Injection may cause side effects which could affect your ability to drive.You may feel tired or weak after using Decintas 50 Injection this could affect your ability to drive.

Kidney:CAUTION

Decintas 50 Injection should be used with caution in patients with kidney disease. Dose adjustment of Decintas 50 Injection may be needed. Please consult your doctor.

Liver:CONSULT YOUR DOCTOR

There is limited information available on the use of Decintas 50 Injection in patients with liver disease. Please consult your doctor.

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 364.

Decitabine. High Wycombe, Bucks: Janssen-Cilag Ltd.; 2012 . view

Decitabine. Netherlands: Pharmachemie B.V.; 2006 . view

Central Drugs Standard Control Organisation . view